Peptides for women over 40 and perimenopause: what the evidence shows

Perimenopause usually starts in the mid forties and is often cited as lasting four to eight years. Estrogen swings high and low before it falls for good, and progesterone drops earlier because ovulation becomes irregular. That hormonal noise produces the hot flashes, night sweats, fragmented sleep and mood swings.

Several other things happen in the same decade and get blamed on the ovaries. Growth hormone output has been falling since the twenties. Muscle mass declines by a commonly cited 3 to 8 percent per decade after 30, faster after menopause. Skin collagen falls, with a widely quoted figure of roughly 30 percent lost in the first five years after the final period.

Peptides can plausibly reach the second group: growth hormone, muscle, skin and weight. They do not reach the first.

Hormone therapy means estrogen, with a progestogen if there is a uterus, and it is the treatment with controlled trial evidence for hot flashes, night sweats and bone density. Current menopause society guidance supports it for symptomatic women under 60 or within ten years of menopause with no contraindication. Peptides have no controlled data for any of those endpoints.

The overlap comes after the hormone decision is made. A woman on hormone therapy who still sleeps badly, or wants to shift body composition, is the person clinics add a secretagogue for. One interaction matters here: the tirzepatide label notes that oral contraceptive absorption drops for four weeks after starting and after each dose increase, and many perimenopausal women still use hormonal contraception.

The line that does not move is mechanism. Secretagogues act on the pituitary, GHK-Cu on fibroblasts, PT-141 on melanocortin receptors in the brain. None touches an estrogen or progesterone receptor.

The pairing most often sold to women in this age group is ipamorelin with CJC-1295 without DAC, injected before bed on an empty stomach. Reported doses are 100 to 300 mcg of ipamorelin and 100 to 200 mcg of CJC-1295, with 100 mcg of each in one syringe as the standard nightly protocol for 8 to 16 weeks. Both amplify the pituitary's own pulses, and deeper sleep within one to two weeks is the most consistent early report.

The evidence in women is where it thins out. Ipamorelin's human pilot studies were in healthy men. The sermorelin trial clinics lean on enrolled men and women aged 55 to 71 and found higher IGF-1 and a modest lean mass gain over 16 weeks. No trial of any secretagogue has been run in perimenopausal women, and none has measured sleep as a primary outcome with ipamorelin. Oral estrogen also lowers IGF-1 through its effect on the liver, while transdermal estrogen does not, so the route of hormone therapy changes what a secretagogue shows on bloodwork.

The compound pages ask for IGF-1, fasting glucose and HbA1c at baseline and at four to six weeks, and a stop for any new lump, persistent carpal tunnel symptoms or a cancer diagnosis. Breast cancer is the relevant history, because every secretagogue page lists a hormone sensitive cancer in the past as a reason not to raise IGF-1. Ipamorelin vs CJC-1295, the stack page and best peptides for sleep cover the protocol detail.

GHK-Cu is the exception on this page, because its best human trial was run in women. Topical GHK-Cu cream improved skin thickness, elasticity and wrinkles in women with photoaged skin over 12 weeks, and a separate comparison found it outperformed vitamin C and retinoic acid for collagen production. Products use 0.5 to 3 percent once or twice daily, with texture changes at three to six weeks and firmness at eight to twelve.

Injectable GHK-Cu is a different proposition. Community protocols report 1 to 2 mg daily subcutaneously for 4 to 8 weeks, with very common stinging and bruising and no human safety data at all. Copper accumulation is a theoretical concern with long use, and anyone with Wilson disease or another copper disorder avoids it by any route. Hair thinning is another common perimenopause complaint, and GHK-Cu for hair covers the thinner evidence there; best peptides for skin ranks the topical options.

Semaglutide and tirzepatide are the only compounds here with large trials that mostly enrolled women. Roughly two thirds or more of the participants in STEP 1 and SURMOUNT-1 were female, so for once the headline numbers apply. Semaglutide 2.4 mg produced about 15 percent average weight loss over 68 weeks; tirzepatide produced 15, 19.5 and 20.9 percent at 5, 10 and 15 mg over 72 weeks. Fat redistributes toward the abdomen after menopause, and these drugs do not care why the weight arrived.

The trade-off matters more in this group than any other. Reviews estimate 30 to 40 percent of weight lost on a GLP-1 drug may be fat-free mass, and the STEP 1 DEXA substudy put the lean fraction at roughly 39 percent. Resistance training and protein are the standard counters, and no human trial shows that adding ipamorelin, sermorelin or any secretagogue prevents the loss. Weight loss of any kind also tends to lower bone density, a second reason lifting belongs in the plan. GLP-1 muscle loss and GLP-1 side effects go deeper.

One practical note: the semaglutide label advises stopping at least two months before a planned pregnancy, which is relevant to anyone in early perimenopause who has not ruled pregnancy out.

PT-141, sold as Vyleesi, is the only peptide approved for a sexual indication, and the approval is specifically for premenopausal women with hypoactive sexual desire disorder. The RECONNECT trials enrolled over 1,200 women and found a modest but real improvement in desire scores at 1.75 mg injected as needed. Nausea hit about 40 percent of participants, and blood pressure rose by roughly 6 mmHg systolic for up to 12 hours. Smaller trials in postmenopausal women showed similar signals, but that group is not in the label, so after menopause it is off-label use with weaker data.

Epithalon and NAD+ are the longevity entries in most protocols marketed to women over 40. Epithalon's telomere result is a cell culture finding from one research group, never shown in a living adult; its plausible effect is on melatonin rhythm and sleep, reported at 5 to 10 mg daily for 10 to 20 days once or twice a year. NAD+ is not a peptide, and injected NAD+ at 50 to 100 mg has a single pharmacokinetic study behind it. Neither has any data in perimenopause, and neither is likely to move a symptom that estrogen withdrawal is causing.

Pregnancy and breastfeeding rule out every research peptide, because none has reproductive safety data, and tesamorelin is formally contraindicated in pregnancy. Perimenopausal pregnancies happen because ovulation is irregular, not absent; standard guidance is contraception until 12 months without a period after 50, or 24 months under 50. A personal breast cancer history is the other hard stop for the growth hormone class and the angiogenic healing peptides, as are peptides safe lays out by class.

Cost is the part clinics describe last. Secretagogue protocols are commonly quoted at a few hundred dollars a month, branded GLP-1 drugs cost considerably more without coverage, and insurance rarely pays for a peptide clinic protocol of any kind. Hormone therapy, by comparison, is generic and inexpensive.

A sensible sequence puts the evaluation first: a clinician who treats menopause, a decision on hormone therapy, then sleep, lifting and protein. Peptides come after that, aimed at one residual goal with a measurable endpoint and a date to reassess. Peptides for beginners and how to buy peptides cover the practical side.